India's Largest Database on New Projects
Lupin in pact with NeuClone
1 June 2011: Lupin has signed a licensing agreement with Sydney based NeuClone Pty for cell-line technology.
A private specialty life-science company, NeuClone will provide the exclusive proprietary cell-line technology to be developed into bio-similar drugs targeting cancer. Biologicals are drugs made in cells and bio-generics are products similar to innovative biological medicine.
With about six to eight proteins in its pipeline, Lupin is looking to develop these biological products keeping an eye on the still-evolving regulatory framework in developed markets such as the US, European Union and Japan.
Source: Hindu Business Line